Anita Villani
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
BACKGROUND Digital Health Tools (DHTs), including wearables and mobile apps, offer promising avenues for personalized care and real-time monitoring, but user engagement and clinical utility—especially in pediatric populations—remain unclear. Li-Fraumeni syndrome (LFS) is a genetic mutation in the TP53 tumor suppressor gene, predisposing individuals to cancer, requiring lifelong surveillance and associated psychological stress. OBJECTIVE We evaluated engagement with DHTs in a cancer genetics clinic for families affected by LFS and explored their utility for patients and clinicians. Our goal was to identify insights that could inform future integration of DHTs in chronic disease populations and contribute to research. METHODS We conducted an observational study (January-December 2022) involving patients with LFS and family members aged 5 years and older. Participants received an Empatica EmbracePlus smartwatch and a suite of self-report surveys assessing psychosocial well-being at varying frequencies (ie, daily, weekly, etc). We used survival analysis to characterize engagement over time across age, TP53 status, and previous cancer history. Generalized additive models were used to explore physiological patterns relative to cancer surveillance events. Semistructured interviews provided qualitative insight into user experiences and preferences. RESULTS We enrolled 9 children and 36 adults. Adults wore their smartwatches more often than children (mean 81%, SD 19% vs mean 56%, SD 26%; t 10 . 1 =2 . 72; P = . 02) and were engaged in the study for a longer duration (median retention 153, IQR 119-179; 95% CI 133-177 vs median 77, IQR 36-151; 95% CI 17-171 days; log-rank χ 2 1 =4 . 4; P = . 04). Daily wear time was similar between the 2 groups (mean 17.6, SD 3.1 hours vs mean 15.7, SD 2.9 hours; t 13 . 2 =1 . 70; P = . 11). There were no differences in survey engagement between adults and children, nor were there differences in engagement across TP53 status or previous cancer history. Children reported greater psychosocial burden, with more depressive symptoms (PHQ-9 [Patient Health Questionnaire-9] score mean 10.0, SD 5.2 vs mean 4.2, SD 4.4; t 7 . 8 =2 . 8; P = . 03), worse sleep (PROMIS SRI [patient-reported outcomes measurement information system sleep-related impairment] score mean 22.7, SD 5.9 vs mean 16.5, SD 5.5; t 8 . 1 = − 2 . 58 ; P = . 03), and increased frequency of stress (mean 36.3%, SD 19.9% vs mean 14.3%, SD 19.2%; t 8 . 3 = − 2 . 7; P = . 03) than adults. A suicide alert system was triggered in 5 participants (11%) and prompted timely clinical intervention. Generalized additive model analysis showed individualized yet consistent physiological patterns of stress associated with cancer surveillance. Qualitative feedback from participants identified perceived value in stress awareness, but highlighted challenges with device comfort, functionality, and personalization. CONCLUSIONS DHTs are feasible and can capture clinically meaningful psychological and physiological data in high-risk pediatric and family populations with LFS. They enable timely detection of distress and facilitate targeted interventions. Our findings can inform best practices for patient-centered DHT integration into clinical care, with relevance to pediatric oncology and broader digital health contexts. CLINICALTRIAL
Year:
2025
Genomic features of patients with RRD-HGG treated with salvage therapies ( n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).
Year:
2024
Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after failing ICI monotherapy is unknown. We performed an international study on 75 patients treated with anti–PD-1; 20 are progression free (median follow-up, 3.7 years). After second progression/recurrence ( n = 55), continuing ICI-based salvage prolonged survival to 11.6 months ( n = 38; P P = 0.03). Delayed, sustained responses were observed, associated with changes in mutational spectra and the immune microenvironment. Response to reirradiation was explained by an absence of deleterious postradiation indel signatures (ID8). CTLA4 expression increased over time, and subsequent CTLA4 inhibition resulted in response/stable disease in 75%. RAS–MAPK-pathway inhibition led to the reinvigoration of peripheral immune and radiologic responses. Local (flare) and systemic immune adverse events were frequent (biallelic mismatch-repair deficiency > Lynch syndrome). We provide a mechanistic rationale for the sustained benefit in RRD-HGG from immune-directed/synergistic salvage therapies. Future approaches need to be tailored to patient and tumor biology. Significance: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological and immune properties, which evolve over time. Future research should focus on combinatorial regimens that increase patient survival while limiting immune toxicity. This article is featured in Selected Articles from This Issue, p. 201
Year:
2024
Patients receiving dual-checkpoint inhibition with ipilimumab and anti–PD-1 after failing ICI monotherapy ( n = 24). A, Swimmer's plot for each patient, showing the best documented radiologic response at any time during treatment. Inset, representative radiologic image showing response to dual-checkpoint inhibition. B, Progression-free (PFS2) and overall survival (OS2). C, Normalized CTLA4 expression counts generated using NanoString platform (Methods) for in-house non-RRD, nonmalignant brain controls, and at different time points for RRD-HGG. D, Paired analysis of normalized CTLA4 expression counts before and after anti–PD-1 therapy for the same patient. E, Toxicities (≥CTCAE grade 3) observed in CMMRD and Lynch syndrome patients on dual ICI.
Year:
2024
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
Year:
2024
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
Year:
2024
Patients treated with nivolumab and trametinib ( n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B , Swimmer's plot summarizing events in each patient. C , The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
Year:
2024
Patients receiving dual-checkpoint inhibition with ipilimumab and anti–PD-1 after failing ICI monotherapy ( n = 24). A, Swimmer's plot for each patient, showing the best documented radiologic response at any time during treatment. Inset, representative radiologic image showing response to dual-checkpoint inhibition. B, Progression-free (PFS2) and overall survival (OS2). C, Normalized CTLA4 expression counts generated using NanoString platform (Methods) for in-house non-RRD, nonmalignant brain controls, and at different time points for RRD-HGG. D, Paired analysis of normalized CTLA4 expression counts before and after anti–PD-1 therapy for the same patient. E, Toxicities (≥CTCAE grade 3) observed in CMMRD and Lynch syndrome patients on dual ICI.
Year:
2024
Patients with RRD-HGG treated with ICI ( n = 75). A, Cohort characteristics. B, Flow of patients with RRD-HGGs treated with ICIs and salvage regimens. MEK-i, MEK inhibitor. C, Progression-free (PFS1) and overall survival (OS1) on anti–PD-1/PDL1 monotherapy. D, Overall survival (OS2) for 55 patients progressing on monotherapy stratified by continued ( n = 38) or no ICI ( n = 17). PPAP, polymerase proofreading associated polyposis syndrome; CMMRD, constitutional mismatch repair deficiency syndrome.
Year:
2024
Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after failing ICI monotherapy is unknown. We performed an international study on 75 patients treated with anti–PD-1; 20 are progression free (median follow-up, 3.7 years). After second progression/recurrence ( n = 55), continuing ICI-based salvage prolonged survival to 11.6 months ( n = 38; P P = 0.03). Delayed, sustained responses were observed, associated with changes in mutational spectra and the immune microenvironment. Response to reirradiation was explained by an absence of deleterious postradiation indel signatures (ID8). CTLA4 expression increased over time, and subsequent CTLA4 inhibition resulted in response/stable disease in 75%. RAS–MAPK-pathway inhibition led to the reinvigoration of peripheral immune and radiologic responses. Local (flare) and systemic immune adverse events were frequent (biallelic mismatch-repair deficiency > Lynch syndrome). We provide a mechanistic rationale for the sustained benefit in RRD-HGG from immune-directed/synergistic salvage therapies. Future approaches need to be tailored to patient and tumor biology. Significance: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological and immune properties, which evolve over time. Future research should focus on combinatorial regimens that increase patient survival while limiting immune toxicity. This article is featured in Selected Articles from This Issue, p. 201
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (21)
Daniel A. Morgenstern
Royal Marsden NHS Foundation Trust
Raymond H. Kim
Associate Professor
University Health Network
Ryuma Tanaka
Assistant Professor
Nationwide Children's Hospital
David Malkin
University of Toronto
Derek S. Tsang
Staff Radiation Oncologist
-
Uri Tabori
Section Head of Neuro-Oncology
Hospital for Sick Children
David Ziegler
Professor
University of New South Wales
Adam Shlien
Wellcome Sanger Institute
Ute Bartels
University of Toronto
Kim Erika Nichols
Full Member
St. Jude Children's Research Hospital
Carl Koschmann
University of Michigan Medical School
Michal Zapotocky
University Hospital in Motol
Gad Getz
Broad Institute
Eric Bouffet
Neuro-Oncologist
Hospital for Sick Children
Birgit Ertl-Wagner
Radiologist-in-Chief
Hospital for Sick Children
Vijay Ramaswamy
Associate Professor
University of Toronto
Trevor J. Pugh
Professor
University Health Network
Anirban Das
Hospital for Sick Children
Stephen Friend
Senior Scientist/ International Scholar
Hospital for Sick Children
Peter B. Dirks
-
Yosef Maruvka
Assistant professor
Technion - Israel Institute of Technology
Make your next move.
Prepare your application
Review drafts before you send them.